Ruti Aga handed six-year ban: forged prescription turned a two-year case into a career-ending sanction

Ethiopian marathon runner Ruti Aga has been handed a six-year ban by the Athletics Integrity Unit (AIU), and the sanction is not really about a prohibited substance at all. According to the AIU statement issued on Thursday, a sample taken after she won a half marathon in China in March returned an adverse finding. When the athlete was asked to explain, the documents she produced were not merely weak — they dismantled the credibility of her entire medical defence.

The arithmetic of the sanction is the most important part of the story. A two-year ban was imposed for the presence violation, and a separate four-year ban for tampering with the investigation. Two plus four equals six. Had Aga simply done what a properly managed athlete does — keep genuine medical records, time the treatment correctly, and apply for a Therapeutic Use Exemption where appropriate — the case could have been substantially shorter, or might never have arisen. The forged paperwork closed that door permanently.

Aga had been provisionally suspended since 10 September, and the six-year ban is also dated from that day. At 32, she will be close to 38 by the time she is eligible to return — effectively the end of an elite career, especially in a national set-up as deep as Ethiopia's women's marathon pool.

The substance, and a technical error in the reporting

The substance at the centre of the case is methylprednisolone. It has widely been described as a "prohibited steroid" and as performance-enhancing by WADA. That is imprecise. Methylprednisolone is a glucocorticoid, listed under class S9 of the WADA Prohibited List — not an anabolic steroid under S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally.

The distinction matters enormously. It means the case turns on route of administration and timing relative to competition, not on doping in the conventional sense. A therapeutic knee injection given out of competition is entirely lawful, provided records are genuine and residues have cleared by race day. Aga therefore had a legitimate defensive pathway: documentation of the knee treatment, the date of injection, and an explanation of the washout period. Because the documents were fabricated, the one defence that could have worked became the evidence against her.

Two years, then four

Under the World Athletics Anti-Doping Rules and the 2026 WADA Code, presence of a Specified Substance without proven intent carries a two-year sanction — precisely what Aga received for the presence violation. Tampering carries a standard four-year sanction, which the panel applied for the fabricated prescription and the misleading statements given during interview. The two run concurrently, producing six years.

The arithmetic tells us the panel rejected the no-significant-fault mitigation that could have reduced the presence sanction further. It also tells us the panel treated the tampering as fully culpable. There is a near-paradox here: forged documents are themselves circumstantial evidence of an intent to conceal, yet they did not aggravate the presence sanction — they simply triggered an entirely separate one.

The "doctor" who was a family member

The most striking element of the case is the identity of the prescribing physician. The prescription was issued by a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace. The clinic named on the document did not exist, and the institution said to have issued the pad explicitly disowned it when the AIU enquired.

Verification failed at three independent levels: the prescriber was not a registered doctor, the clinic did not exist, and the institution whose pad was allegedly used denied any connection to it. Against that, an argument of therapeutic necessity collapses — a document that is false at three levels is not proof of medical need but evidence of something else entirely.

The knee injury is the root cause, and it is systemic

Knee pathology is a familiar failure mode in high-volume marathoners. Glucocorticoid injections are the cheapest and most accessible way to suppress inflammation and get back to racing within weeks. The plausible medical explanation is precisely why the forgery is decisive: a genuine treatment would have been defended with genuine records, a team physician and a filing trail. Instead, what emerged was an informal arrangement — a relative, an old pad, no registration.

This is not a filing error. It is the signature of an athlete operating without credentialed medical support, and it points to a governance gap that runs through much of the East African road-racing circuit. A properly managed athlete either holds a TUE or observes the route-specific washout period. Neither appears to have happened, and when questioned, documents were manufactured.

The knee problem is also unlikely to have appeared suddenly in March. The claim of an old pad from a former workplace suggests a repeated pattern of informal treatment rather than a single lapse.

The career ledger

Before this case, Aga was a genuine major-marathon contender. Her 2026 Tokyo Marathon title is the headline achievement, alongside three second-place finishes at World Marathon Majors. She was second in Berlin in 2026 in a reported time of around 2:18:34, and ran around 2:20:40 in Tokyo in 2026 — figures not officially confirmed in the source material for this case.

Technically, the violation is anchored to a March race in a later year. Absent a finding of earlier use, results before that date — including the 2026 Major win — are not automatically annulled. The AIU statement does not set out the disqualification scope. Standard practice, however, means her result and prize money from the Chinese race are very likely voided, along with ranking points accrued thereafter.

Her record is now bifurcated: a genuinely elite marathon CV on one side, and a sanction that makes her commercially radioactive on the other, in a sport where distance-running sponsorship is already thin.

Ethiopian depth means the competitive landscape barely moves

Sportingly, the ban changes almost nothing. Ethiopia's women's marathon pool is extraordinarily deep, and a 2:18–2:20 performer is not automatically selectable even when available. Aga's three Major second places were commercial-tier results, not championship conversions. Her removal does not alter Ethiopia's medal capacity by any measurable margin.

What is changing is the integrity landscape. AIU cases involving tampering are clustering, suggesting the enforcement frontier has shifted from detection to document verification. Aga's case belongs to a recognisable family of East African road-racing cases in which an initial substance violation is compounded by a fabricated or altered explanation.

China's label-race circuit is now a high-scrutiny zone. It combines large appearance-fee budgets, deep East African elite fields and active AIU testing. The appearance-fee economy and the testing economy are colliding in the same races, and Aga's case is the visible result.

Language, translation and the interview room

Four years of the sanction flow from statements made under questioning, not from documents alone. The language and translation conditions of AIU interviews with Ethiopian athletes are a recurring point of contention in international sports jurisprudence. In this case, though, that line of defence is weak: no translation issue explains why a named clinic did not exist.

Is an appeal realistic?

A CAS appeal window exists, typically around 21 days from the reasoned decision, but its prospects are poor. The tampering finding is document-based, and document findings are the hardest element of a sanction to overturn. Backdating the ban to 10 September is a procedural adjustment, not a concession — provisional suspension time counts against the total, so the athlete gains nothing in real terms.

A proportionate sanction or a striking one?

Six years for a glucocorticoid with no proven endurance benefit will be cited both as evidence of AIU rigour and as evidence of disproportionate enforcement against African road runners. Technically it is neither disproportionate nor unprecedented: it is two separate sanction bands run concurrently — two years for presence, four for tampering. The Code deliberately sets a heavy penalty for tampering because it attacks the integrity of the testing system itself.

What remains a legitimate question is whether athletes operating in informal East African road-racing structures receive the education, legal support and formal medical backup that would prevent decisions like these. On the evidence of this case, the answer appears to be no.

The AIU statement does not specify the year of the March race, the year the ban expires, or the full scope of disqualification. No national federation statement has been quoted. Only the family member is named; whether the athlete's agent or management was investigated is unknown.

What is clear is that this case signals a shift in anti-doping enforcement: the question is no longer only what was in an athlete's body, but what the athlete produced to explain it. Ruti Aga gave an answer that was not true — and that answer became the most expensive mistake of her career. The substance cost her two years. The paperwork cost her the other four.